Vasculitis & polymyalgia rheumatica
Exploring the genetic interaction between ERAP1 / ERAP2 and HLA-B*52:01 in Takayasu arteritis
Authors' conclusion
These results suggest that the genetic profile of Takayasu arteritis differs from other MHC-I-opathies, supporting its classification as a distinct subtype within this group of immune-mediated diseases.
Study context
- Population
- Participants of a large multi-ancestral GWAS of TAK
- Comparison
- Genetic interaction between ERAP1/ERAP2 polymorphisms and HLA-B*52:01 in TAK
- Outcome
- Genetic interaction between ERAP1/ERAP2 and HLA-B*52:01 in TAK
Methodological detailsmulti-ancestral GWAS data, genetic interaction analyses, meta-analysis across populations, stratified by HLA-B*52:01 status
- Multi-ancestral GWAS data
- Genetic interaction analyses
- Meta-analysis across populations
- Stratified by HLA-B*52:01 status
Pooled result
As reported in the abstract
ERAP1/ERAP2 × HLA-B*52:01 interaction
- No significant genetic interactions between ERAP1 or ERAP2 and HLA-B*52:01 in TAK, contrasting with other MHC-I-opathies
Further pooled results
Association of ERAP1/ERAP2 with TAK (incl. dominant/recessive models and HLA-B*52:01-stratified)
- No significant associations detected, incl. dominant or recessive models or after stratifying by HLA-B*52:01 status
Original publication
Exploring the genetic interaction between ERAP1 / ERAP2 and HLA-B*52:01 in Takayasu arteritis. Rheumatology (Oxford). Published 16 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →